Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
How has Dallas Diabetes Research Center's publication output changed over time?
ScholarIQpublication output · 2003–2022
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2022.
1
1
1
1
1
1
5
1
20032005200620092016201820212022
Who are the most-cited researchers behind Dallas Diabetes Research Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Dallas Diabetes Research Center?
ScholarIQmost cited works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll
New England Journal of Medicine. 20166,751 CitationsOPEN ACCESS
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara McGowan, Julio Rosenstock, Marie Thi Dao Tran, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F. Kushner
New England Journal of Medicine. 20214,748 CitationsOPEN ACCESS
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman, Bing Liu, Xuewei Cui, Katelyn Brown
New England Journal of Medicine. 20211,951 CitationsOPEN ACCESS
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, Kelley R. Branch, Stefano Del Prato, Nardev S. Khurmi, Carolyn S.P. Lam, Renato D. Lópes, John J.V. McMurray, Richard E. Pratley, Julio Rosenstock, Hertzel C. Gerstein
The Lancet Diabetes & Endocrinology. 20211,549 CitationsOPEN ACCESS
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason Brett, Marcin Zychma, Lawrence Blonde
The Lancet. 20091,499 Citations
How much of the research on Dallas Diabetes Research Center is open access?
ScholarIQopen access share
75%OPEN ACCESS
Gold
0%
Green
33%
Hybrid
8%
Bronze
33%
Closed
25%
Related on ScholarIQ
Diabetes Treatment and Management
Top Topic
Diabetes Management and Research
Top Topic
Metabolism, Diabetes, and Cancer
Top Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Top Topic
Pancreatic function and diabetes
Top Topic
Hyperglycemia and glycemic control in critically ill and hospitalized patients
Top Topic